Stockman Wealth Management Inc. grew its stake in shares of AstraZeneca (NYSE:AZN) by 2.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 116,447 shares of the company’s stock after purchasing an additional 2,877 shares during the quarter. AstraZeneca accounts for 1.9% of Stockman Wealth Management Inc.’s investment portfolio, making the stock its 15th biggest position. Stockman Wealth Management Inc.’s holdings in AstraZeneca were worth $4,072,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently modified their holdings of the business. Pinnacle Wealth Planning Services Inc. acquired a new position in shares of AstraZeneca in the fourth quarter worth about $101,000. Delpha Capital Management LLC acquired a new position in shares of AstraZeneca in the fourth quarter worth about $152,000. Calton & Associates Inc. acquired a new position in shares of AstraZeneca in the fourth quarter worth about $181,000. Whittier Trust Co. lifted its stake in shares of AstraZeneca by 420.0% in the first quarter. Whittier Trust Co. now owns 5,200 shares of the company’s stock worth $182,000 after acquiring an additional 4,200 shares in the last quarter. Finally, Green Square Capital LLC acquired a new position in shares of AstraZeneca in the fourth quarter worth about $200,000. Institutional investors own 15.59% of the company’s stock.
Several research analysts recently commented on AZN shares. Zacks Investment Research upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, March 20th. Jefferies Group upgraded AstraZeneca from a “hold” rating to a “buy” rating and boosted their price target for the stock from $28.43 to $36.70 in a research note on Monday, March 19th. ValuEngine cut AstraZeneca from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 2nd. BMO Capital Markets set a $40.00 price target on AstraZeneca and gave the stock a “buy” rating in a research note on Tuesday, February 20th. Finally, Leerink Swann boosted their price target on AstraZeneca from $36.00 to $38.00 and gave the stock a “market perform” rating in a research note on Tuesday, February 6th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and thirteen have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $38.12.
Shares of AstraZeneca opened at $36.88 on Friday, Marketbeat.com reports. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.73 and a quick ratio of 0.62. The stock has a market capitalization of $93.31 billion, a P/E ratio of 8.62, a PEG ratio of 1.94 and a beta of 0.61. AstraZeneca has a fifty-two week low of $28.43 and a fifty-two week high of $37.30.
AstraZeneca (NYSE:AZN) last announced its quarterly earnings data on Friday, May 18th. The company reported $0.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.28 by $0.20. The firm had revenue of $5.18 billion during the quarter, compared to analyst estimates of $5.24 billion. AstraZeneca had a return on equity of 30.73% and a net margin of 12.61%. AstraZeneca’s quarterly revenue was down 4.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.99 earnings per share. equities research analysts anticipate that AstraZeneca will post 1.7 earnings per share for the current fiscal year.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.